摘要
糖尿病黄斑水肿(DME)是糖尿病患者视力丧失的主要原因,早期有效治疗DME对患者视力愈后至关重要。目前抗血管内皮生长因子(VEGF)药物是治疗首选,但需多次注射,造成沉重的社会经济负担。糖尿病视网膜病变临床研究网提出了亚临床DME的概念,发现其进展为临床有意义黄斑水肿的风险显著增加。但西医缺乏有效的干预手段,为此团队率先将亚临床DME的概念引入国内,分析亚临床DME的病因病机,以中医治未病思想为指导,探讨亚临床DME的中医药干预策略,以期引起国内学者的重视,将DME的防治工作前移。
Diabetic macular edema(DME)is themain cause of vision loss in people with diabetes.Early and effective treatment of DME is very important for the recovery of visual acuity.At present,anti-vascular endothelial growth factor(VEGF)drugs are the first choice for treatment,but they need to be injected many times,resulting in heavy social and economic burden.The concept of subclinical DME was proposed by the Diabetic Retinopathy Clinical Research Network,and it was found that the risk of progression to clinically significant macular edema increased significantly.However,western medicine lacks effective intervention means,so we are the first to introduce the concept of subclinical DME into China,analyzing the etiology and pathogenesis of subclinical DME,discussing the Traditional Chinese Medicine intervention strategies of subclinical DME under the guidance of"Preventive treatment of diseases",in order to attract the attention of domestic scholars and advance the prevention and treatment of DME.
作者
王建伟
接传红
高健生
陶永健
WANG Jianwei;JIE Chuanhong;GAO Jiansheng(Eye Hospital,China Academy of Chinese Medical Sciences,Beijing 100040,China)
出处
《中国中医眼科杂志》
2021年第6期432-434,439,共4页
China Journal of Chinese Ophthalmology
基金
首都卫生发展科研专项(2020-3-4184,2020-2-4182)
北京市中医药科技发展资金项目(JCZX-2020-14)。
关键词
亚临床糖尿病黄斑水肿
临床有意义的黄斑水肿
中医
subclinical diabetic macular edema
clinically significant macular edema
Traditional Chinese Medicine
